Sanofi's Dengue Vaccine Gets WHO Backing In People Previously Infected

Label restriction, discussions with regulators should keep vaccine in use, Sanofi suggests; Philippines suspended its vaccination program after data showed product can worsen disease in those not previously exposed to infection.

Dengue virus vaccine

Sanofi is trying to assuage concerns about its Dengvaxia dengue vaccine with a label recommendation against use in individuals who have never been infected with dengue and discussions with health and regulatory authorities.

The company has faced questions about the vaccine since announcing the results of a new analysis of long-term clinical trial...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Vaccines

More from Pink Sheet